H.C. Wainwright analyst Raghuram Selvaraju downgraded CervoMed (CRVO) to Neutral from Buy without a price target saying the “disappointing” neflamapimod clinical data “creates uncertainty.” The cites the RewinD-LB study failure for the downgrade.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVO: